Pfizer looks to electronics to streamline trials

Pfizer ($PFE) is trying out a new "all-electronic" approach in a clinical study involving the approved overactive bladder pill Detrol, with an eye toward finding ways to streamline its trials for experimental drugs, the Wall Street Journal reports. Nobody spends more on R&D than Pfizer, giving the drug giant reason to look for ways of doing clinical research more efficiently. The company's ($PFE) Detrol study will rely heavily on the use of smartphones and computers to allow patients to report their progress, patient recruitment will be done online, and one group from the University of California, San Francisco, will manage the trial. How's that for efficient? Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.